Drug Profile

Rilzabrutinib - Principia Biopharma

Alternative Names: PRN 1008; SAR-444671; Wayrilz

Latest Information Update: 24 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Principia Biopharma
Developer Principia Biopharma; Sanofi
Class 2 ring heterocyclic compounds; Amines; Anti-inflammatories; Antianaemics; Antiasthmatics; Eye disorder therapies; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Idiopathic thrombocytopenic purpura; Sickle cell anaemia; Autoimmune haemolytic anaemia; Pemphigus; Pemphigus vulgaris; Immunoglobulin G4-related disease
New Molecular Entity Yes

Marketed Idiopathic thrombocytopenic purpura
Phase III Autoimmune haemolytic anaemia; Sickle cell anaemia
Phase II Asthma; Chronic urticaria; Focal segmental glomerulosclerosis; Graves' disease; Immunoglobulin G4-related disease; Lipoid nephrosis
No development reported Liver disorders
Discontinued Atopic dermatitis; Pemphigus; Pemphigus vulgaris

17 Oct 2025 Sanofi receives CHMP recommendation for EU approval for rilzabrutinib in immune thrombocytopenia (In adults)
15 Oct 2025 Sanofi plans a phase III trial for Idiopathic thrombocytopenic purpura in Japan in October 2025 (NCT07216079)
24 Sep 2025 Sanofi plans a phase III RILIEF trial in Immunoglobulin G4 related disease (PO, Tablets) (NCT07190196)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com